Bioterrorism: Pivotal clinical issues - Consensus review of the society of infectious diseases pharmacists

Pharmacotherapy

Volumn 23, Issue 3, 2003, Pages 274-290

  Terriff, Colleen M ^a   Schwartz, Mike D ^b   Lomaestro, Ben M ^c,d  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c ALBANY MEDICAL CENTER   (United States)

^d MC85 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; ANTIBIOTIC AGENT; ANTITOXIN; AZITHROMYCIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; IMIPENEM; PENICILLIN G; PROCAINE PENICILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SMALLPOX VACCINE; TETANUS TOXIN; TETRACYCLINE; VANCOMYCIN;

ACCESS TO INFORMATION; ANTHRAX; ANTIMICROBIAL THERAPY; ARTICLE; BACILLUS ANTHRACIS; BACTERIUM ISOLATION; BIOLOGICAL WARFARE; CLINICAL FEATURE; CLOSTRIDIUM BOTULINUM; DISASTER; DOSE TIME EFFECT RELATION; EMERGENCY TREATMENT; EPIDEMIOLOGICAL DATA; HEALTH CARE MANAGEMENT; HEALTH PROGRAM; HUMAN; IMMUNIZATION; INFECTION PREVENTION; INTERNET; MICROBIOLOGICAL EXAMINATION; NEPHROTOXICITY; PEER REVIEW; PHARMACIST; PLAGUE; SMALLPOX; TULAREMIA; YERSINIA PESTIS;

ADULT; AGED; ANTHRAX; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOTERRORISM; BOTULISM; CHILD; FEMALE; HUMANS; INFECTION CONTROL; MALE; MIDDLE AGED; PLAGUE; SMALLPOX; SOCIETIES, PHARMACEUTICAL; UNITED STATES;

EID: 0037370050     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.3.274.32097     Document Type: Article

References (48)

1. Torok TJ, Tauxe RV, Wise RP, et al. A large community outbreak of salmonellosis caused by intentional contamination of restaurant salad bars. JAMA 1997;278:389-95.
2. Centers for Disease Control and Prevention. Bioterrorism alleging use of anthrax and interim guidelines for management: United States, 1998. MMWR Morb Mortal Wkly Rep 1999;281:787-9.
3. Centers for Disease Control and Prevention. Biological and chemical terrorism: strategic plan for preparedness and response - recommendations of the CDC strategic planning workgroup. MMWR Morb Mortal Wkly Rep 2000;49(no. RR-4):1-14.
4. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science 1994;266:1202-7.
5. Inglesby TV, O'Toole T, Henderson DA, et al. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002;287:2236-52.
6. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for clinical evaluation of persons with possible anthrax, November 2001. MMWR Morb Mortal Wkly Rep 2001;50:941-8.
7. Balter S, Bridges C, Earls J, et al. Clinical issues in the prophylaxis, diagnosis and treatment of anthrax. Emerg Infect Dis 2002;8:222-5.
8. Webb GF, Blaser MJ. Mailborne transmission of anthrax: modeling and implications. Proc Natl Acad Sci USA 2002;99:7027-32.
9. Jernigan JA, Stephens DS, Ashford DA, et al. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg Infect Dis 2001;7:933-44.
10. Barakat LA, Quentzel HL, Jernigan JA, et al. Fatal inhalational anthrax in a 94-year-old Connecticut woman. JAMA 2002;287:863-8.
11. Ibrahim KH, Brown G, Wright DH, Rotschafer JC. Bacillus anthracis: medical issues of biologic warfare. Pharmacotherapy 1999;19:690-701.
12. Dixon TC, Meselson M, Guillemin J, Hanna PC. Anthrax. N Engl J Med 1999;341:815-26.
13. Centers for Disease Control and Prevention. Update: investigation of bioterrorism-related anthrax and interim guidelines for exposure management and antimicrobial therapy, October 26, 2001. MMWR Morb Mortal Wkly Rep 2001;50:909-19.
14. Inglesby TV, Henderson DA, Bartlett JG, et al. Anthrax as a biological weapon: medical and public health management. JAMA 1999;281:1735-45.
15. Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalational anthrax. J Infect Dis 1993;167:1239-42.
16. Choe CH, Bouhaouala SS, Brook I, et al. In vitro development of resistance to ofloxacin and doxycycline in Bacillus anthracis Sterne [letter]. Antimicrob Agents Chemother 2000;44:1766.
17. 60Co-gamma-irradiated mice [abstr]. In: Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2000:56.
18. Heine HS, Dicks R, Byrne WR. In vitro activity of daptomycin, sparfloxacin, quinupristin-dalfopristin and other antibiotics against Bacillus anthracis strains [abstr]. In: Program and abstracts of the 40th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2000:167.
19. Heine HS, Dicks R, Andrews G. In vitro activity of oritavancin (LY333328), levofloxacin, meropenem, GAR 936 and linezolid against strains of Bacillus anthracis [abstr]. In: Program and abstracts of the 41st interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2001:173.
20. Swartz MN. Recognition and management of anthrax: an update. N Engl J Med 2001;345:1621-6.
21. Freedman A, Afonja O, Chang MW, et al. Cutaneous anthrax associated with microangiopathic hemolytic anemia and coagulopathy in a 7-month-old infant. JAMA 2002;287:869-74.
22. Bartlett JG. What's hot and what's not. Presented at the 39th annual meeting of the Infectious Diseases Society of America, San Francisco, CA, October 26, 2001. Summarized by David Haburchak. Available from www.medscape.com. Accessed January 15, 2003.
23. Anonymous. Considerations for distinguishing influenza-like illness from inhalational anthrax. MMWR Morb Mortal Wkly Rep 2001;50:984-6.
24. Food and Drug Administration. FDA briefing package. Antiinfective drug products advisory committee meeting. Rockville, MD: Food and Drug Administration, July 28, 2000. Available from www.FDA.gov/ohrms/dockets/ac/cder00.htm#antiinfective. Accessed June 1, 2002.
25. Centers for Disease Control and Prevention. Update: investigation of anthrax associated with intentional exposure an interim public health guidelines, October 2001. MMWR Morb Mortal Wkly Rep 2001;50:889-97.
26. Benavides S, Nahata MC. Anthrax: safe treatment for children. Ann Pharmacother 2002;36:334-7.
27. Centers for Disease Control and Prevention. Update: Investigation of bioterrorism-related anthrax and adverse events from antimicrobial prophylaxis. MMWR Morb Mortal Wkly Rep 2001;50:973-6.
28. U.S. Army Medical Research Institute of Infectious Diseases. Medical management of biological casualties handbook, 4th ed. Ft. Dedrick, MD: U.S. Army Medical Research Institute of Infectious Diseases, 2001.
29. Arnon SS, Schechter R, Inglesby TV. Botulinum toxin as a biological weapon: medical and public health management. JAMA 2001;285:1059-70.
30. Franz DR, Jahrling PB, Friedlander AM, et al. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 1997;278:399-411.
31. Shapiro RJ, Hatheway C, Becher J, Swerdlow DL. Botulism surveillance and emergency response. JAMA 1997;278:433-5.
32. Inglesby TV, Grossman R, O'Toole T. A plague on your city: observations from TOPOFF. Clin Infect Dis 2001;32:436-45.
33. Inglesby TV, Dennis DT, Henderson DA, et al. Plague as a biological weapon: medical and public health management. JAMA 2000;283:2281-90.
34. Heath DG, Anderson GW, Mauro JM, et al. Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine 1998;16:1131-7.
35. Weber DJ, Rutala WA. Risks and prevention of nosocomial transmission of rare zoonotic diseases. Clin Infect Dis 2001;32:446-56.
36. Inglesby TV, Henderson DA, Bartlett JG, et al. Smallpox as a biological weapon: medical and public health management. JAMA 1999;281:2127-37.
37. McKinney WP, Bia FJ, Stewart C, et al. Bioterrorism: an update for clinicians, pharmacists and emergency management planners. Emerg Med Consensus Reports Nov 1, 2001;8-9. Available from www.ahcpub.com/ahc_root_html/hot/archive/hic0300.html. Accessed June 1, 2002.
38. Breman JG, Henderson DA. Poxvirus dilemmas: monkeypox, smallpox and biological terrorism. N Engl J Med 1998;339:556-9.
39. Alibek K. Biohazard. New York: Random House Inc., 1999.
40. Buller RM. Poxviruses. In: Armstrong D, Cohen J, eds. Infectious diseases. London: Harcourt, 2000:8.7.4-8.7.6.
41. Lane JM, Ruben FL, Neff JM, et al. Complications of smallpox vaccine, 1968: national surveillance in the United States. N Engl J Med 1969;281:1201-8.
42. Frey SE, Couch RB, Tacket CO, et al. Clinical response to undiluted and diluted smallpox vaccine. N Engl J Med 2002;346:1265-74.
43. Chapman S, ed. Aerospace world. United States Air Force almanac. Air Force Magazine 2002;May:27. Available from www.AFA.org/almanac/almanac.pdf. Accessed June 1, 2002.
44. Dixon CW. Smallpox in Tripolitania, 1946: an epidemiological and clinical study of 500 cases, including trials of penicillin treatment. J Hyg 1948;46:351-77.
45. Dennis DT, Inglesby TV, Henderson DA, et al. Tularemia as a biological weapon: medical and public health management. JAMA 2001;285:2763-73.
46. Feldman KA, Enscore RE, Lathrop SL, et al. An outbreak of primary pneumonic tularemia on Martha's Vineyard. N Engl J Med 2001;324:1601-6.
47. Teeter DS. Bioterrorism preparedness: answers for the health-system pharmacist. Am J Health-Syst Pharm 2002;59:928-30.
48. Terriff CM, Tee AM. City-wide pharmaceutical preparation for bioterrorism. Am J Health-Syst Pharm 2001;58:233-7.